4-氯-2-吡啶-4-基嘧啶-5-羧酸乙酯 | 204394-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-2-吡啶-4-基嘧啶-5-羧酸乙酯
• 英文名称: 4-chloro-2-pyridin-4-yl-pyrimidine-5-carboxylic acid ethyl ester
• 英文别名: Ethyl 4-chloro-2-(pyridin-4-yl)pyrimidine-5-carboxylate；ethyl 4-chloro-2-pyridin-4-ylpyrimidine-5-carboxylate
• CAS: 204394-36-5
• 化学式: C₁₂H₁₀ClN₃O₂
• mdl: MFCD11047092
• 分子量: 263.683
• InChiKey: ZHGXCAJGZVCTHU-UHFFFAOYSA-N

物化性质

• 熔点：
  98～99℃
• 沸点：
  341.7±34.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-氯-2-吡啶-4-基嘧啶-5-羧酸乙酯 在 palladium dihydroxide sodium azide 、 氢气 、 二异丁基氢化铝 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 四氯化碳 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors

  摘要：

  The structure-based design, synthesis, and biological activity of novel inhibitors of S-adenosyl homocysteine/methylthioadenosine (SAH/MTA) nucleosidase are described. Using 6-substituted purine and deaza purines as the core scaffolds, a systematic and structure guided series of modifications provided low nM inhibitors with broad-spectrum antimicrobial activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.006
• 作为产物：
  描述：

  4-amidinopyridine hydrochloride 在 氯化亚砜 、 potassium ethoxide 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 为溶剂， 生成 4-氯-2-吡啶-4-基嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors

  摘要：

  The structure-based design, synthesis, and biological activity of novel inhibitors of S-adenosyl homocysteine/methylthioadenosine (SAH/MTA) nucleosidase are described. Using 6-substituted purine and deaza purines as the core scaffolds, a systematic and structure guided series of modifications provided low nM inhibitors with broad-spectrum antimicrobial activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.006

文献信息

• 2,4,5,-trisubstituted pyrimidine derivatives
  申请人：——

  公开号：US20020099207A1

  公开（公告）日：2002-07-25

  The invention relates to compounds of the formula 1 wherein R 1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, —S-lower alkyl, —S(O) 2 -lower alkyl, —N(R)—(CH 2 ) n —N(R) 2 , —O—(CH 2 ) n —N(R) 2 , —N(R) 2 , or a cyclic tertiary amine of the group 2 which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker —O(CH 2 ) n —; R 2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 3 /R 3 ′ is, independently from each other, hydrogen or lower alkyl; R 4 is independently from each other halogen, trifluoromethyl or lower alkoxy; R 5 is hydrogen or lower alkyl; R is, independently from each other, hydrogen or lower alkyl; X is —C(O)N(R)— or —N(R)C(O)—; Y is —O—, —S—, —SO 2 —, - or —N(R)—; n is 1,2,3 or 4; and m is 0,1 or 2; or a pharmaceutically acceptable acid addition salt thereof. The compound of the invention has affintity to the NK1 receptor and is therefore suitable in the treatment of diseases related to this recepor.

  该发明涉及具有下列结构的化合物1： 其中 R1是较低的烷基、较低的烷氧基、吡啶基、嘧啶基、苯基、—S-较低的烷基、—S(O)2-较低的烷基、—N(R)—(CH2)n—N(R)2、—O—(CH2)n—N(R)2、—N(R)2或者2组的环状三级胺，该组可能包含一个额外的异原子，选自N、O或S，且该组可以通过连接基团—O(CH2)n—与嘧啶环连接； R2是氢、较低的烷基、较低的烷氧基、卤素或三氟甲基； R3/R3'分别是氢或较低的烷基； R4是独立的卤素、三氟甲基或较低的烷氧基； R5是氢或较低的烷基； R是独立的氢或较低的烷基； X是—C(O)N(R)—或—N(R)C(O)—； Y是—O—、—S—、—SO2—或—N(R)—； n是1、2、3或4； m是0、1或2； 或其药学上可接受的酸盐。该化合物具有对NK1受体的亲和力，因此适用于治疗与该受体相关的疾病。
• Novel inhibitors of AP-1 and NF-κB mediated gene expression: structure–activity relationship studies of ethyl 4-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate
  作者：Moorthy S.S Palanki、Paul E Erdman、Anthony M Manning、Arnold Ow、Lynn J Ransone、Cheryl Spooner、Carla Suto、Mark Suto

  DOI：10.1016/s0960-894x(00)00312-7

  日期：2000.8

  In an effort to identify novel inhibitors of AP-1 and NF-kappa B mediated transcriptional activation, several analogues of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate (1) were synthesized and tested in two in vitro assays. The 2-(2'-thienyl) substituted compound (II) was identified as the most potent in this series. (C) 2000 Elsevier Science Ltd. All rights reserved.
• PYRIMIDINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1339698A2

  公开（公告）日：2003-09-03
• US6787539B2
  申请人：——

  公开号：US6787539B2

  公开（公告）日：2004-09-07
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002042280A2

  公开（公告）日：2002-05-30

  The invention relates to compounds of the general formula (I) wherein R1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, -S-lower alkyl, -S(O)¿2?-lower alkyl, -N(R)-(CH2)n-N(R)2, -O-(CH2)n-N(R)2, -N(R)2, or a cyclic tertiary amine which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker -O(CH2)n-; R?2¿ is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R3/R3' is, independently from each other, hydrogen or lower alkyl; R4 is independently from each other halogen, trifluoromethyl or lower alkoxy; X is-C(O)N(R) or -N(R)C(O)-; Y is -O-,-S-,-SO¿2?-, or -N(R)-; n is 1,2,3 or 4; and m is 0,1 or 2; and to pharmaceutically acceptable acid addition salts thereof. They have a good affitity to the NK1 receptor and they are therefore suitable in the treatment of diseases, related to this receptor.